Kaneka Medical America LLC
14
3
4
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 14 trials
100.0%
+13.5% vs industry average
7%
1 trials in Phase 3/4
29%
2 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Prospective Multi-center Single Arm Study for Subjects With Chronic Subdural Hematoma Treated With i-ED COILs, Either Alone or in Combination With Burr-holes or Mini-craniotomy
Role: lead
Kaneka Endovascular Embolization and Protection
Role: lead
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
Role: lead
Post Approval Study of Lixelle for the Treament of Dialysis-Related Amyloidosis
Role: lead
A Feasibility Study to Evaluate the Safety of the KNP-1000 Apheresis System in Severe Preeclampsia
Role: lead
Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System
Role: lead
LDL-Apheresis for FSGS CardioRenal Outcomes
Role: collaborator
Ubiquinol as a Metabolic Resuscitator in Post-Cardiac Arrest
Role: collaborator
Ubiquinol (Reduced COQ10) for Patients With Sepsis
Role: collaborator
Removal of Anti-Angiogenic Proteins in Preeclampsia Before Delivery
Role: collaborator
Assessing Bioavailability of CoQ10 Supplementation in Burn Patients
Role: collaborator
Treating Congestive Heart Failure Using a Device to Remove Cholesterol
Role: collaborator
Guidewire for Chronic Total Occlusion
Role: collaborator
Effects of Low-density Lipoprotein (LDL) Apheresis on Inflammatory and Lipid Markers
Role: collaborator
All 14 trials loaded